Trials / Recruiting
RecruitingNCT07226726
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
Mesenchymal Stem Cell Exosome Treatment of Congenital Myasthenic Syndrome
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Detailed description
Single Arm non-controlled study. Patients are prospectively evaluated then treated. Outcomes are tracked after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AlloEx exosomes | This is an intranasal treatment of exosomes derived from mesenchymal stem cells. |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2025-11-10
- Last updated
- 2025-11-10
Locations
3 sites across 2 countries: United States, Antigua and Barbuda
Source: ClinicalTrials.gov record NCT07226726. Inclusion in this directory is not an endorsement.